China Health Industry Investment Fund
3
95M
3
- Areas of investment
Summary
The fund is generally included in less than 2 deals every year. The high activity for fund was in 2018. The usual things for fund are deals in the range of 50 - 100 millions dollars.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the China Health Industry Investment Fund, startups are often financed by Sequoia Capital China, YF Capital (Yunfeng Capital), Tencent Holdings. The meaningful sponsors for the fund in investment in the same round are Sequoia Capital China, Qiming Venture Partners, Lilly Asia Ventures. In the next rounds fund is usually obtained by Qiming Venture Partners, Juren Capital, Goldport Capital.
Among the most successful fund investment fields, there are Social Impact, Medical Device. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Medlinker, Beijing Allcure Medical Technology, Microtech Medical The fund has specific favorite in a number of founders of portfolio startups.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Investments by industry
- Medical (3)
- Health Care (3)
- Cloud Computing (1)
- Therapeutics (1)
- Manufacturing (1) Show 2 more
- Investments by region
-
- China (3)
- Peak activity year
- 2018
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 1B
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Beijing Allcure Medical Technology | 24 Jul 2018 | Health Care, Medical, Cloud Computing, Therapeutics | Early Stage Venture | 108M | China, Beijing, Dongcheng District |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.